Previous 10 | Next 10 |
Gainers: MediciNova (NASDAQ:MNOV) +27%. Puma Biotechnology (NASDAQ:PBYI) +6%. GoHealth (NASDAQ:GOCO) +5%. Chindata Group Holdings Limited (NASDAQ:CD) +4%. Nutanix (NASDAQ:NTNX) +4%. Losers: Autodesk (NASDAQ:ADSK) -13%. Esperion Therapeutics (NASDAQ:ESPR) -10%. Cl...
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid ( BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients - - In patients with metabolic syndrome NEXLETOL lowered hemogl...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Esperion Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Esperion Therapeutics, inc (NASDAQ: ESPR) Q3 2021 Earnings Call Nov 2, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics, inc (ESPR) Q3 2021 Earnings Call Transcrip...
Esperion Therapeutics, Inc. (ESPR) Q3 2021 Results Conference Call November 02, 2021 08:00 AM ET Company Participants Ben Church - Investor Relations & Corporate Communications Sheldon Koenig - President & Chief Executive Officer Rick Bartram - Chief Financial Officer Dr. Joanne Foody...
Esperion's (NASDAQ:ESPR) Q3 2021 earnings beat was helped by sales of its two cholesterol-lowering drugs. The company reported net product revenue in the quarter composed of sales of Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) of $10.9M, up from $4.8M in th...
Esperion Therapeutics (NASDAQ:ESPR): Q3 GAAP EPS of -$2.62 beats by $0.22. Revenue of $14.41M (+276.2% Y/Y) beats by $2.52M. Press Release For further details see: Esperion Therapeutics EPS beats by $0.22, beats on revenue
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Acc...
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021. AHA Scientific Sessions 2021 Bempedoic Acid ...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...